Eva Szabo

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Primer: first do no harm--when is it appropriate to plan a cancer prevention clinical trial?
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, National Cancer Institute, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 5:348-56. 2008
  2. pmc Use of markers for the detection and treatment of lung cancer
    Jason S Vourlekis
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 6130 Executive Blvd, Rm 2132, Bethesda, MD 20892, USA
    Dis Markers 20:71-85. 2004
  3. pmc Phase II cancer prevention clinical trials
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Semin Oncol 37:359-66. 2010
  4. ncbi request reprint Selecting targets for cancer prevention: where do we go from here?
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Room 2132, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 6:867-74. 2006
  5. pmc Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Cancer Prev Res (Phila) 3:128-31. 2010
  6. pmc Altered histology provides a positive clinical signal in the bronchial epithelium
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA
    Cancer Prev Res (Phila) 4:775-8. 2011
  7. doi request reprint Higher levels of the anti-inflammatory protein CC10 are associated with improvement in bronchial dysplasia and sputum cytometric assessment in individuals at high risk for lung cancer
    Jiping Chen
    Cancer Prevention Fellowship Program, Office of Preventive Oncology, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:1590-7. 2008
  8. pmc Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
    Arun Rajan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Lancet Oncol 15:191-200. 2014
  9. pmc Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Cancer Prev Res (Phila) 6:448-54. 2013
  10. pmc 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors
    Anish Thomas
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 19:1487-93. 2013

Detail Information

Publications37

  1. doi request reprint Primer: first do no harm--when is it appropriate to plan a cancer prevention clinical trial?
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, National Cancer Institute, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 5:348-56. 2008
    ..This Review identifies the issues that are critical for decision-making when clinical trials in human beings are being contemplated and provides a framework that can be applied in making these decisions...
  2. pmc Use of markers for the detection and treatment of lung cancer
    Jason S Vourlekis
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 6130 Executive Blvd, Rm 2132, Bethesda, MD 20892, USA
    Dis Markers 20:71-85. 2004
    ..This review examines the current status of markers of lung cancer risk, early detection, and prognosis, and their applicability to current standards of clinical care...
  3. pmc Phase II cancer prevention clinical trials
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Semin Oncol 37:359-66. 2010
    ..However, the goal of all such trials is to provide evidence of interference with the development of cancer and to identify safety signals that would limit the benefit from interventions...
  4. ncbi request reprint Selecting targets for cancer prevention: where do we go from here?
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Room 2132, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 6:867-74. 2006
    ....
  5. pmc Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Cancer Prev Res (Phila) 3:128-31. 2010
    ..The critical issue of how these data can be used to further drug development is discussed...
  6. pmc Altered histology provides a positive clinical signal in the bronchial epithelium
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA
    Cancer Prev Res (Phila) 4:775-8. 2011
    ..e., regression), which occurred in former, but not current, smokers with sputum atypia. This Perspective discusses the strength of the clinical signal provided by this observation and its implications for further drug development...
  7. doi request reprint Higher levels of the anti-inflammatory protein CC10 are associated with improvement in bronchial dysplasia and sputum cytometric assessment in individuals at high risk for lung cancer
    Jiping Chen
    Cancer Prevention Fellowship Program, Office of Preventive Oncology, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:1590-7. 2008
    ..We investigated whether changes in CC10 expression correlate with regression of bronchial dysplasia and/or improvement in sputum abnormalities as measured by image cytometry...
  8. pmc Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
    Arun Rajan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Lancet Oncol 15:191-200. 2014
    ..We investigated the efficacy of cixutumumab, a fully human IgG1 monoclonal antibody targeting the insulin-like growth factor 1 receptor in thymic epithelial tumours after failure of previous chemotherapy...
  9. pmc Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Cancer Prev Res (Phila) 6:448-54. 2013
    ..Thus, altering the dose of erlotinib retained most of its preventive and therapeutic efficacy, and based on prior clinical studies, is likely to reduce its toxicity...
  10. pmc 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors
    Anish Thomas
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 19:1487-93. 2013
    ..The primary objective of this study was to assess the usefulness of early [(18)F]-FDG PET to monitor treatment efficacy and its correlation with Response Evaluation Criteria in Solid Tumors (RECIST) in patients with TETs...
  11. doi request reprint A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors
    Arun Rajan
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:2344-51. 2012
    ..To determine the safety and tolerability of olaparib with cisplatin and gemcitabine, establish the maximum tolerated dose (MTD), and evaluate the pharmacodynamic and pharmacokinetic profile of the combination...
  12. ncbi request reprint Criteria of evidence to move potential chemopreventive agents into late phase clinical trials
    Ronan J Kelly
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Drug Targets 12:1983-8. 2011
    ..In this review we identify the issues that are critical to decision-making prior to embarking on late phase prevention clinical trials and provide a framework for making such decisions...
  13. pmc Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Chest 143:e40S-60S. 2013
    ..Chemoprevention refers to the use of specific agents to reverse, suppress, or prevent the process of carcinogenesis. This article reviews the major agents that have been studied for chemoprevention...
  14. pmc Characterization and management of cardiac involvement of thymic epithelial tumors
    Anish Thomas
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Thorac Oncol 8:246-9. 2013
    ..The purpose of this study was to describe our single-institution experience of the clinical presentation, treatment, and follow-up of cardiac involvement in patients with TETs...
  15. pmc Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors
    Giuseppe Giaccone
    Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 29:2052-9. 2011
    ..Antitumor activity of histone deacetylase (HDAC) inhibitors in this disease has been documented, including one patient with thymoma treated with the pan-HDAC inhibitor belinostat...
  16. pmc Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research
    Antonello Punturieri
    Division of Lung Diseases, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Bethesda, MD 20892 7952, USA
    J Natl Cancer Inst 101:554-9. 2009
    ....
  17. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
    ....
  18. pmc Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine
    Elad Sharon
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, USA
    Head Neck Oncol 2:12. 2010
    ..We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine...
  19. ncbi request reprint Chemoprevention of lung cancer: new directions
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, Room 2132, Bethesda, MD 20892, USA
    Recent Results Cancer Res 163:172-81; discussion 264-6. 2003
    ..Further understanding of lung cancer biology will be critical to the success of future clinical trials...
  20. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
    ..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...
  21. ncbi request reprint The association between the anti-inflammatory protein CC10 and smoking status among participants in a chemoprevention trial
    Jiping Chen
    Cancer Prevention Fellowship Program, National Cancer Institute, 6130 Executive Boulevard, Room 2132, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 16:577-83. 2007
    ..These results show that sustained smoking cessation is associated with higher plasma CC10 levels, suggesting that at least some of the damage associated with tobacco smoke may be repaired by long-term smoking cessation...
  22. doi request reprint Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 7:972-9. 2008
    ..Finally, combining suboptimal doses of Iressa with suboptimal doses of vorozole (an aromatase inhibitor) or targretin (a retinoid X receptor agonist) yielded greater chemopreventive efficacy than any of these agents given alone...
  23. pmc Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study
    V Paul Doria-Rose
    Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 115:5007-17. 2009
    ..However, these findings were based on incomplete follow-up, and each trial on its own was underpowered to detect a modest mortality benefit...
  24. ncbi request reprint A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors
    Maurice A Wright
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 11:4144-50. 2005
    ..In preclinical studies, sequential exposure to irinotecan (CPT-11) then fluorouracil (5-FU) is superior to concurrent exposure or the reverse sequence; a 24-hour infusion of CPT-11 may be better tolerated than shorter infusions...
  25. ncbi request reprint Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule
    Xiao Du Guo
    National Cancer Institute Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, MD 20889 5105, USA
    Cancer Chemother Pharmacol 52:79-85. 2003
    ..To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV)...
  26. ncbi request reprint Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung
    Tsg Hui Chang
    Molecular Physiology and Biophysics Unit, National Institute of Neurologic Diseases and Stroke, Bethesda, Maryland 20892, USA
    Clin Cancer Res 8:1206-12. 2002
    ....
  27. ncbi request reprint MUC1 expression in lung cancer
    Eva Szabo
    Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    Methods Mol Med 74:251-8. 2003
  28. ncbi request reprint How should we move the field of chemopreventive agent development forward in a productive manner?
    Frank Louis Meyskens
    Department of Internal Medicine Hematology Oncology and Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA
    Recent Results Cancer Res 166:113-24. 2005
    ..We examine the problems associated with testing chemoprevention agents in humans and offer a process and guidelines that may better inform the logical development of this relatively young clinical field...
  29. ncbi request reprint Prevention of mouse lung tumors by budesonide and its modulation of biomarkers
    Michael A Pereira
    Department of Pathology, Medical College of Ohio, HEB, Room 200F, 3055 Arlington Avenue, Toledo, OH 43614 5806, USA
    Carcinogenesis 23:1185-92. 2002
    ..Thus, short-term treatment with budesonide modulated biological and molecular end-points in lung tumors that might be developed further as biomarkers for its clinical chemopreventive efficacy in the lung...
  30. ncbi request reprint Predicting success in cancer prevention trials
    Jason S Vourlekis
    J Natl Cancer Inst 95:178-9. 2003
  31. ncbi request reprint A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium
    Stephen Lam
    Department of Respiratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:6502-11. 2004
    ..Preclinical studies suggest that inhaled budesonide may be an effective chemopreventive agent for lung cancer. We conducted a phase IIb study to determine the effects of inhaled budesonide in smokers with bronchial dysplasia...
  32. pmc Comparative bioavailability of sulindac in capsule and tablet formulations
    Joel M Reid
    Mayo Clinic, College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 17:674-9. 2008
    ..These data support the use of sulindac capsules, which can be readily prepared with matching placebos, in future blinded chemoprevention trials...
  33. ncbi request reprint Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
    Jean L Grem
    Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 23:1885-93. 2005
    ..To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks...
  34. ncbi request reprint Diet and cancer: the disconnect between epidemiology and randomized clinical trials
    Frank L Meyskens
    Department of Medicine, Chao Family Comprehensive Cancer Center, Hematology Oncology, University of California, Irvine, Building 44, Route 81, 101 City Drive Cancer Center, Orange, California 92668, USA
    Cancer Epidemiol Biomarkers Prev 14:1366-9. 2005
    ..We need to be much more self-critical in the important and critical assessment of dietary compounds and their role in cancer prevention given the very high appeal for this approach both within the lay and scientific communities...
  35. ncbi request reprint A phase I study of myo-inositol for lung cancer chemoprevention
    Stephen Lam
    Department of Respiratory Medicine, British Columbia Cancer Agency, British Columbia, Canada
    Cancer Epidemiol Biomarkers Prev 15:1526-31. 2006
    ..A phase I, open-label, multiple dose, dose-escalation clinical study was conducted to assess the safety, tolerability, maximum tolerated dose, and potential chemopreventive effect of myo-inositol in smokers with bronchial dysplasia...
  36. ncbi request reprint Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition)
    Jhanelle Gray
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, MRC 4W, Room 4046, Tampa, FL 33612, USA
    Chest 132:56S-68S. 2007
    ..Chemoprevention is the use of specific agents to reverse, suppress, or prevent the process of carcinogenesis. This article reviews the major agents that have been studied for chemoprevention...
  37. ncbi request reprint Proliferative changes in chemoprevention trials: learning from secondary endpoints
    Eva Szabo
    J Natl Cancer Inst 99:1565-7. 2007